Kaplan-Meier survival curve analysis showed that the median overall survival (OS) of NSCLC patients with TP53 mutations (n=217) was 10 months compared to 14 months for patients with the wildtype TP53 (n = 133), but, the differences were not statistically significant [hazard ratio (HR) = 1.13, confidence interval (CI) = 0.93-1.37 and P = 0.209; Figure 2A]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.